Comparative Efficacy and Safety of Low-dose Fluticasone Propionate and Montelukast in Children with Persistent Asthma
| Autor: | Kathleen M. Hanson, William Lincourt, Lisa D. Edwards, Jacqueline R. Carranza Rosenzweig, Nancy K. Ostrom, Courtney Crim, Bruce A. Decotiis |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Cyclopropanes
Male medicine.medical_specialty Evening Hydrocortisone medicine.drug_class Acetates Sulfides Severity of Illness Index Fluticasone propionate Pulmonary function testing Double-Blind Method Internal medicine medicine Humans Anti-Asthmatic Agents Child Montelukast Morning Asthma Fluticasone business.industry medicine.disease Bronchodilator Agents Respiratory Function Tests respiratory tract diseases Androstadienes Treatment Outcome Anesthesia Pediatrics Perinatology and Child Health Quinolines Corticosteroid Female business medicine.drug |
| Zdroj: | The Journal of Pediatrics. 147:213-220 |
| ISSN: | 0022-3476 |
| Popis: | To evaluate efficacy, safety, health outcomes, and cost-effectiveness of fluticasone propionate (FP) versus montelukast (MON) in 342 children (6 to 12 years of age) with persistent asthma.Randomized, double-blind, 12-week study of treatment with FP inhalation powder 50 mug twice daily or MON chewable 5 mg once daily for 12 weeks.Compared with MON, FP significantly increased mean percent change from baseline FEV1 (forced expiratory volume in 1 second) (P=.002), morning PEF (peak expiratory flow) (P=.004), evening PEF (P=.020), and percent rescue-free days (P=.002) at end point, and it significantly reduced nighttime symptom scores (P.001) and mean total (P=.018), and nighttime (P.001) albuterol use. Withdrawals from the study were more frequent with MON (21%) than with FP (13%). Adverse events (69% vs 71%) and mean end point to baseline 12-hour urinary cortisol excretion ratios were similar. Parents and physicians were more satisfied with FP treatment than with MON (P=.006 and P=.016, respectively, at Week 12). Mean total daily asthma-related cost per patient in the FP group was approximately one-third of that in the MON group ($1.25 vs $3.49).FP was significantly more effective than MON in improving pulmonary function, asthma symptoms, and rescue albuterol use. Both therapies had similar safety profiles. Parent- and physician-reported satisfaction ratings were higher with FP treatment, and asthma-related costs were lower. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect